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Abstract
Background: The serine/threonine kinase PIM1 has been implicated as an oncogene in various human cancers 
including lymphomas, gastric, colorectal and prostate carcinomas. In mouse models, Pim1 is known to cooperate with 
c-Myc to promote tumorigenicity. However, there has been limited analysis of the tumorigenic potential of Pim1 
overexpression in benign and malignant human prostate cancer cells in vivo.
Methods: We overexpressed Pim1 in three human prostate cell lines representing different disease stages including 
benign (RWPE1), androgen-dependent cancer (LNCaP) and androgen-independent cancer (DU145). We then analyzed 
in vitro and in vivo tumorigenicity as well as the effect of Pim1 overexpression on c-MYC transcriptional activity by 
reporter assays and gene expression profiling using an inducible MYC-ER system. To validate that Pim1 induces 
tumorigenicity and target gene expression by modulating c-MYC transcriptional activity, we inhibited c-MYC using a 
small molecule inhibitor (10058-F4) or RNA interference.
Results: Overexpression of Pim1 alone was not sufficient to convert the benign RWPE1 cell to malignancy although it 
enhanced their proliferation rates when grown as xenografts in vivo. However, Pim1 expression enhanced the in vitro 
and in vivo tumorigenic potentials of the human prostate cancer cell lines LNCaP and DU145. Reporter assays revealed 
increased c-MYC transcriptional activity in Pim1-expressing cells and mRNA expression profiling demonstrated that a 
large fraction of c-MYC target genes were also regulated by Pim1 expression. The c-MYC inhibitor 10058-F4 suppressed 
the tumorigenicity of Pim1-expressing prostate cancer cells. Interestingly, 10058-F4 treatment also led to a reduction of 
Pim1 protein but not mRNA. Knocking-down c-MYC using short hairpin RNA reversed the effects of Pim1 on Pim1/MYC 
target genes.
Conclusion: Our results suggest an in vivo role of Pim1 in promoting prostate tumorigenesis although it displayed 
distinct oncogenic activities depending on the disease stage of the cell line. Pim1 promotes tumorigenicity at least in 
part by enhancing c-MYC transcriptional activity. We also made the novel discovery that treatment of cells with the c-
MYC inhibitor 10058-F4 leads to a reduction in Pim1 protein levels.
Background
Pim1 is a constitutively active serine/threonine kinase [1],
whose activity is therefore primarily regulated at the level
of expression and stability. Pim1 enhances cell cycle pro-
gression by phosphorylating Cdc25A, Cdc25C, p21cip1,
p27kip1 and c-Tak1 [2-5] or by associating with protein
complexes required for mitosis [6]. Pim1 also inhibits
apoptosis by phosphorylating apoptotic proteins includ-
ing Bad [7], FOXO3a [5] and ASK1 [8]. PIM1 has been
implicated as an oncogene whose expression is dysregu-
lated in several human cancers including lymphomas,
gastric, colorectal and prostate cancers [9].
The oncogenic activity of Pim1 was first discovered in
lymphomagenesis. PIM1 was identified as a non-immu-
noglobulin (IG)/BCL6 translocation partner gene and
6p21, its chromosomal locus, was amplified in B-cell lym-
phomas [10,11]. PIM1 is also known to be a target locus
for aberrant somatic hypermutation in some lymphomas
[12-15]. Eμ-Pim1 transgenic mice engineered to overex-
press Pim1 in lymphocytes develop T cell lymphomas
and cooperate with another proto-oncogene Myc  to
accelerate the disease progression [16-18].
In human prostate cancer, PIM1 expression is known to
be elevated in ~50% of human prostate cancer specimens
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and its cooperation with MYC was also proposed [19].
Prostate cancer induced by mouse prostate-specific over-
expression of c-MYC  oncogene demonstrated Pim1
mRNA upregulation, suggesting possible synergistic
effect between two oncogenes [20]. However, the onco-
genic activity of Pim1 itself in prostate cancer using in
vivo models has not been fully characterized. One study
used PC3 human prostate carcinoma cells to show that
Pim1 overexpression accelerates tumorigenicity in these
cells associated with elevated levels of c-MYC and the
phosphorylation of proteins involved in protein synthesis
[21]. Here we sought to determine the effects of Pim1
overexpression on the tumorigenic potential of human
prostate cells representing distinct stages of disease pro-
gression, including benign/non-tumorigenic, tumori-
genic/androgen-sensitive and tumorigenic/androgen-
independent stages. Using these cells, we analyzed the
effects of Pim1 on in vitro and in vivo tumorigenicity as
well as c-MYC transcriptional activity.
Methods
Cell lines and cell culture
C e l l  l i n e s  w e r e  o b t a i n e d  f r o m  A m e r i c a n  T y p e  C u l t u r e
Collection. Vector control, Pim1 or kinase dead mutant
P i m 1  ( K 6 7 M ) - o v e r e x p r e s s i n g  c e l l s  w e r e  g e n e r a t e d  a s
described [22]. pBabe-Puro-MYC-ER plasmid (gift from
Dr. Gerard Evan, University of California at San Fran-
cisco, CA, USA) was used to generate retroviruses and
infect RWPE1-Neo and RWPE1-Pim1 cells to generate
RWPE1-Neo/MYC-ER and RWPE1-Pim1/MYC-ER cells
and the cells were maintained as described [23]. To acti-
vate c-MYC in chimeric MYC-ER protein, 100 nM of 4-
hydroxytamoxifen (4OHT) in ethanol was added to the
cells. LNCaP and DU145 cells were maintained in RPMI
with 10% fetal bovine serum.
Western blot analyses
Western blotting was performed as described [22] using
following antibodies: anti-Pim1 (mouse, 1:500, Santa
Cruz), anti-beta-Actin (goat, 1:1000, Santa Cruz), anti-
phospho-p21 (rabbit, 1:1000, Santa Cruz), anti-p21
(mouse, 1:1000, Santa Cruz), anti-cyclin E (rabbit, 1:1000,
Santa Cruz), anti-androgen receptor (rabbit, 1:500, Santa
Cruz) and anti-c-Myc (mouse, 1:500, Santa Cruz).
Cell cycle analysis
Cell cycle was analyzed by fluorescence-activated cell
sorting (FACS) as described [24].
MTT cell proliferation assay
MTT Cell Proliferation Assay Kit was purchased from
ATCC and assay was performed in accordance with the
manufacturer's protocol. Individual absorbance was mea-
sured with plate photometer (Bio-tek).
Soft agar assays
These were performed as described [25]. 100 × 103 and 20
× 103 of LNCaP and DU145 cells were used, respectively
and total number of colonies (≥ cutoff sizes) was counted.
For c-Myc inhibitor (10058-F4) treatment, 50 × 103 of
LNCaP and DU145 were used and 100 uM 10058-F4 in
0.25% DMSO or 0.25% DMSO alone was added. Three
random low power view-fields were selected and each
number of colonies (≥ cutoff sizes) was added.
Xenografts in nude mice
Male nude (nu/nu) mice were obtained from Charles
River laboratories. 3 × 106, 3 × 106 and 5 × 106 of RWPE1,
LNCaP and DU145 cells were mixed with 200 μl of Matri-
gel (BD Biosciences), respectively. Cells were injected
subcutaneously in both flanks of nude mice. Tumor vol-
umes and cross-sectional areas were calculated as
described [26,27]. Animal care and experiments were car-
ried out according to the protocols approved by the Insti-
tutional Animal Care and Use Committees at Vanderbilt
University.
Histology and immunohistochemical analyses
Nude mice were sacrificed after 30-38 (RWPE1) or 6-8
(LNCaP and DU145) weeks. Xenografted lesions were
taken, photographed, fixed in formalin (10%) and embed-
ded in paraffin for subsequent histology as described
[28]. Immunohistochemical analyses were performed as
described [28] using following antibodies: activated Cas-
pase 3 (rabbit, 1:500, Cell Signaling), Ki67 (rabbit, 1:50,
abcam) and phospho-Histone H3 (rabbit, 1:500, Upstate).
Analysis of androgen-dependent proliferation
15,000 LNCaP cells were plated on 24 well plates. The
n e x t  d a y ,  c e l l s  w e r e  w a s h e d  w i t h  p h o s p h a t e - b u f f e r e d
saline (PBS) and phenol red-free RPMI media with char-
coal-striped serum was added for androgen starvation.
After 2-day starvation, DHT (5α-Dihydrotestosterone) or
carrier (ethanol) was added. MTT assays were performed
from next day (Day 1). MTT values of DHT-treated cells
were divided by those of carrier-untreated cells and tripli-
cate data per group were analyzed.
DHT treatment and quantitative RT-PCR
For DHT treatment, LNCaP cells were washed with
phosphate-buffered saline (PBS) and phenol red-free
RPMI media with charcoal-striped serum was added for
androgen starvation. After 2-day starvation, DHT (0.1, 1,
10 and 100 nM) or carrier (ethanol) was added and the
cells were incubated for 2 days. Total RNA isolation,
reverse transcription and subsequent quantitative PCR
were performed as described [24]. The following primers
were used: Prostate specific antigen (PSA) forward (5'-
CAA CCC TGG ACC TCA CAC CTA-3'), PSA reverse
(5'-GGA AAT GAC CAG GCC AAG AC-3'); humanKim et al. BMC Cancer 2010, 10:248
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GAPDH forward (5'-ATG GAA ATC CCA TCA CCA
TCT T-3'), human GAPDH reverse (5'-CGC CCC ACT
TGA TTT TGG-3'); LAMC2 forward (5'-GGA TGA
GAA TCC TGA CAT TGA GTG T-3'), LAMC2 reverse
(5'-GTC GTG CGG ATC GTT GTA GA-3'); MT1F for-
ward (5'-ACC TGC CCC ACT GCT TCT T-3'), MT1F
reverse (5'-TTG CAA GCC GAG GAG AGA CT-3');
UPP1 forward (5'-TCT GGA GGC AGC CTA TGC A-3'),
UPP1 reverse (5'-GCA AAC ACC GAG GAC TCC AT-
3'); CDKN1C forward (5'-GCC TCT GAT CTC CGA
TTT CTT C-3'), CDKN1C reverse (5'-CAT CGC CCG
ACG ACT TCT-3'); CUL3 forward (5'-AGA TTT TGA
GGC TCC TTT TTT GG-3'), CUL3 reverse (5'-AAA
ATT TCT GGC TTT CCA TCT GAA-3'); SOD2 forward
(5'-GCT GCA CCA CAG CAA GCA-3'), SOD2 reverse
(5'-TCG GTG ACG TTC AGG TTG TTC-3'); VAV3 for-
ward (5'-CTG GTG AAC AAG GGA CAC TCA A-3'),
VAV3 reverse (5'-TTT AGG AGT TCT TCG CAG TCC
ATT-3'); mouse Pim1 (5'-ATT CCG TTT GAG CAC
GAT GAA-3'), mouse Pim1 reverse (5'-TGA AGA GAC
AGT TTG CCT GAA GAA-3'). Each mRNA expression
was normalized with GAPDH expression.
Luciferase assay
300,000 RWPE1 cells were plated on 12 well plates and
grown without supplements (bovine pituitary extract and
epidermal growth factor) for 24 hours. Transient trans-
fection was performed with the following plasmids: c-
Myc-responsive 4× E-box reporter (gift from Dr. Stephen
Hann, Vanderbilt University, TN, USA), pMSCV-MYC
and pMSCV empty vector. After 30 hours, cell lysates
were harvested and luciferase activity was measured
using luciferase assay system (Promega). Luciferase activ-
ity was normalized to protein concentration and tripli-
cate data per group were analyzed.
c-Myc inhibitor treatment
c-Myc inhibitor (10058-F4) was purchased from Sigma.
Cells were plated on 6-well plates and 50, 100 and 200 uM
10058-F4 in 0.5% DMSO or 0.5% DMSO alone was added
on next day when cells were sub-confluent. Cells were
harvested after 20 hours and RT-PCR and western blot-
ting were performed from the isolated mRNA and cell
lysates, respectively.
c-Myc gene silencing with small hairpin RNA (shRNAmir)
Control and Pim1-expressing LNCaP cells were plated on
60 mm dishes. Lentiviral shRNAmirs (Open Biosystems)
against c-MYC and pGIPZ control plasmid were tran-
siently transfected. Transfection efficiency was moni-
tored by GFP fluorescence. After 3 days, cells were
harvested, and mRNA isolation followed by reverse tran-
scription and qRT-PCR and western blotting were per-
formed.
Genechip analysis
Total RNA was isolated from RWPE1-Neo/MYC-ER and
RWPE1-Pim1/MYC-ER cells with and without 24 hr
4OHT treatment. Genechip analysis was performed in
duplicates according to manufacturer's protocol (Affyme-
trix) using U133A chips. Genes whose expressions were
altered at least 1.4-fold with significance (P < 0.005) in
pairwise comparisons were identified.
Statistical analyses
Each group was compared using t-test. Values are consid-
ered statistically significant at P < 0.05. Quantitative vari-
ables are expressed as means + standard deviation while
categorical variables are expressed as numbers (%).
Results
Generation of human prostate cell lines at different disease 
stages, with stable Pim1 overexpression
To examine the effects of Pim1 overexpression on pros-
tate tumorigenesis, we selected three human prostate cell
lines at different cancer disease stages: RWPE1, an
immortalized, benign, androgen-responsive human pros-
tatic epithelial cell line [29]; LNCaP, a tumorigenic,
androgen-responsive human prostate cancer cell line
[30,31]; and DU145, a tumorigenic androgen-indepen-
dent human prostate cancer cell line [32-34]. We stably
expressed Pim1 in all the cell lines and established pools
of Pim-1 expressing and vector control (Neo) cells.
LNCaP and DU145 cells express high levels of c-MYC
endogenously (Figure 1A) but c-MYC levels in the
RWPE1 cells were not detectable by western blot (see Fig-
ure 2B). To examine Pim1 activity, we assessed a known
phosphorylation substrate of Pim1, p21 using a phospho-
specific antibody [3]. Phospho-p21 levels were increased
4-fold in RWPE1-Pim1 cells (Figure 1A), showing
increased kinase activity of Pim1.
Pim1 has been reported to induce polyploidy and chro-
mosomal instability (CIN) in a passage-dependent man-
ner [22,24] and the resultant polyploidy/CIN was shown
to increase in vitro and in vivo tumorigenicity [25]. We
therefore examined the cell cycle profiles of the cells we
used in the tumorigenicity assays in the current study to
ensure that we utilize cells that have not progressed to
polyploidy. As shown in Figure 1B, there were no differ-
ences in ploidy between control and Pim1-expressing
cells and this is probably due to relatively early passage
number (RWPE1, passage 18; LNCaP, passage 27; DU145,
passage 23).
Pim1 promotes proliferation and attenuates apoptosis of 
RWPE1 cells in vivo without malignant conversion
In vitro cell proliferation (MTT) assay showed that there
was no discernible change in cellular proliferation due to
Pim1 expression in RWPE1 cells (Figure 3A). In addition,Kim et al. BMC Cancer 2010, 10:248
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RWPE1-Pim1 cells failed to form colonies in soft agar
assay (data not shown), verifying that in vitro tumorige-
nicity of Pim1-expressing RWPE1 cells is due to poly-
ploidy cells driven by chromosomal instability as shown
previously [25]. When control and Pim1-expressing cells
were grafted in nu/nu nude mice, no tumors formed.
H&E stain however showed increased cellularity in Pim1-
expressing RWPE1 cells (Figure 3B) and immunohis-
tochemical analysis for Ki67 confirmed elevated prolifer-
ation in the tissues of this group (Figure 3C). Apoptosis
was also modestly reduced in the Pim1-expressing
RWPE1 xenografts as shown by immunostaining for acti-
vated Caspase 3 (Figure 3C). These results indicate that
although Pim1 could enhance proliferation and suppress
apoptosis of RWPE1 cells grown as xenografts, it is insuf-
ficient to convert these cells to malignancy.
Pim1 promotes in vitro and in vivo tumorigenicity of LNCaP 
and DU145 cells
We next asked whether Pim1 can enhance the tumorige-
nicity of established malignant prostate cancer cells. We
first tested the androgen-sensitive prostate cancer cell
line LNCaP. Pim1 expression increased the soft agar col-
ony formation rate of LNCaP cells by ~2 fold and also led
Figure 1 Overexpression of Pim1 in human prostate cell lines. (A) Western blots demonstrated Pim1 expression in benign human prostate cell 
line (RWPE1) and human prostate cancer cell lines (LNCaP and DU145). In addition, endogenous levels of c-MYC were upregulated in two cancer cell 
lines. Phosphorylation of p21 was increased in Pim1-expressing RWPE1 cells compared to control cells (Neo). (B) Cell sorting analyses showed that 
there was no difference between control (Neo) and Pim1 cells in cell cycle at the time when the cells were grafted.Kim et al. BMC Cancer 2010, 10:248
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to the formation of larger colonies (Figure 4A). When
grafted subcutaneously in nude mice, LNCaP-Pim1 cells
formed bigger and heavier tumors (Figure 4B and 4C)
with shorter latency (Figure 4D). LNCaP-Pim1 tumors
were also more noticeably hemorrhagic by both gross and
microscopic examination (Figure 4B and 4E). We ana-
lyzed proliferation in the tumors by immunohistochemis-
try for phospho-histone H3. Proliferation was
significantly increased in the LNCaP-Pim1 tumors rela-
tive to the LNCaP-Neo control tumors (8.8% ± 1.2 versus
3.5% ± 1.3, P = 0.003). There was also a trend to reduction
in apoptosis as determined by staining for activated cas-
pase 3 (0.35% ± 0.25 in LNCaP-Pim1 tumors versus 0.57%
± 0.58 in LNCaP-Neo tumors). Thus Pim1 can promote
the tumorigenicity of LNCaP cells. To extend our findings
we also used DU145 cells expressing Pim1 in soft agar
assays. Pim1 expression increased DU145 cell colony
forming potential up to ~6 fold as well as colony size (Fig-
ure 5A). When injected into nude mice, DU145-Pim1
cells also formed larger tumors with a shorter latency
(Figure 5B,C and 5D). Thus Pim1 expression can further
enhance the tumorigenicity of established tumor cells.
Androgen receptor signaling does not affect in vitro 
cellular proliferation but its transcriptional activity is 
induced by Pim1
Pim1 has been reported to modulate androgen receptor
signaling in prostate cancer cells [35,36]. To examine
whether androgen receptor signaling affects Pim1 tum-
origenic function, we compared androgen-dependent cell
proliferation rates between control and Pim1-expressing
LNCaP cells. As shown in Figure 6A, expression of Pim1
or a Pim1 kinase-dead mutant (K67M) did not affect
androgen-stimulated cell proliferation. AR signaling
effects on in vitro cell proliferation could be dissociated
from other AR signaling functions. Therefore next, we
tested androgen receptor transcriptional activity by
examining induction of PSA mRNA expression after 5α-
Dihydrotestosterone (DHT) treatment. LNCaP-Pim1
cells responded to DHT with significantly higher induc-
tion of PSA compared to LNCaP-Neo control cells (Fig-
ure 6B). Notably, LNCaP-K67M cells which express the
Pim1 kinase-dead mutant showed even lower PSA induc-
tion compared to LNCaP-Neo cells (Figure 6B), consis-
tent with the interpretation that the K67M protein
functions as a dominant negative mutant. Western blot
analysis demonstrated that both Pim1- and K67M-
expressing LNCaP cells displayed induction of AR pro-
tein expression compared to control LNCaP-Neo cells
(2.5 fold and 1.7 fold, respectively) (Figure 6C). Therefore,
elevated AR expression can partially explain the increase
in PSA levels in LNCaP-Pim1 cells. Other mechanisms
are probably operative however, since LNCaP-K67M cells
have also increased AR levels but lower PSA expression
than control LNCaP-Neo cells (Figure 6B and 6C). These
results suggest that Pim1 could promote prostate tumori-
genesis by enhancing AR transcriptional activity.
Pim1 enhances c-MYC transcriptional activity
Pim1 tumorigenic function has been intimately linked to
c-Myc in several systems. Pim1 is thought to cooperate
with c-Myc to promote tumorigenicity by increasing c-
Myc protein expression [21,37] or stimulating the binding
of RNA polymerase II leading to increase the transcrip-
tion of c-Myc target genes [38]. T o assess c-MYC tran-
scriptional activity in Pim1-expressing prostate cells we
Figure 2 Increase in c-MYC activity due to Pim1 overexpression. (A) Luciferase assay using c-MYC responsive reporter construct demonstrated 
that Pim1 overexpression induced transcriptional activity of c-MYC but its kinase dead mutant Pim1 (K67 M) showed dramatically repressed c-MYC 
activity compared to control. *P < 0.05. (B) Western blots showed c-MYC expression is undetectable in RWPE1 cells.Kim et al. BMC Cancer 2010, 10:248
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Figure 3 Pim1 expression is insufficient to convert benign human prostate cells (RWPE1) to malignancy. (A) 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay showed there was no difference in in vitro cell proliferation between control and Pim1-expressing RWPE1 
cells. (B) Representative H&E images of grafts. RWPE1-Neo (N = 5); RWPE1-Pim1 (N = 7). Scale bars: 100 μm. (C) Quantitation of proliferation and apop-
tosis in xenografts after immunostaining for Ki67 and activated Caspase 3, respectively. *P < 0.05.Kim et al. BMC Cancer 2010, 10:248
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Figure 4 Pim1 enhances tumorigenicity of androgen-dependent human prostate cancer cells (LNCaP) in vitro and in vivo. (A) Soft agar assay 
showed increased in vitro tumorigenicity of Pim1-expressing LNCaP cells. When control or Pim1-expressing LNCaP cells were subcutaneously grafted 
in nude mice, the latter developed larger tumors in size (B) and weight (C). (D) Kaplan-Meier survival analysis demonstrates slightly accelerated tumor 
onset by Pim1 expression. Numbers in the parentheses indicate the number of replicates or grafts in each group. (E) H&E stains demonstrated that 
Pim1 expression caused more hemorrhagic phenotype than control. *P < 0.05.Kim et al. BMC Cancer 2010, 10:248
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used a c-Myc-responsive 4x-Ebox reporter in luciferase
assays. RWPE1-Pim1 cells demonstrated higher c-MYC
reporter activity compared to RWPE1-Neo cells (Figure
2A). Furthermore, activity of the c-Myc reporter was sup-
pressed in RWPE1-K67M cells consistent with a domi-
nant negative function of the kinase-dead mutant Pim1
(K67M). This dominant negative action of the K67M
mutant is again evident as repression of expression of
Cyclin E, a known c-MYC target gene, in RWPE1-K67M
cells (Figure 2B).
Figure 5 Pim1 enhances tumorigenicity of aggressive human prostate cancer cells (DU145) in vitro and in vivo. (A) Soft agar assay shows in-
creased in vitro tumorigenicity of Pim1-expressing DU145 cells. When control or Pim1-expressing DU145 cells were subcutaneously grafted in nude 
mice (nu/nu), the latter developed larger tumor in size (B and C). (D) Kaplan-Meier survival analysis demonstrates significantly accelerated tumor onset 
by Pim1 expression. Numbers in the parentheses indicate the number of replicates or grafts in each group. *P < 0.01, **P < 0.05.Kim et al. BMC Cancer 2010, 10:248
http://www.biomedcentral.com/1471-2407/10/248
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Figure 6 Role of androgen in proliferation and transcriptional activity of androgen receptor in control and Pim1-expressing LNCaP cells. 
(A) Effect of androgen receptor signaling on cell proliferation. Cell proliferation with or without DHT (5α-Dihydrotestosterone) treatment was analyzed 
in control and Pim1-expressing LNCaP cells. (B) PSA mRNA levels were measured by RT-PCR analysis after the treatment of various dose of DHT. Neo 
vs. Pim1 or Neo vs. K67M was compared. *P < 0.05. (C) Western blots for Pim1, androgen receptor (AR) and Actin in the indicated cell lines.Kim et al. BMC Cancer 2010, 10:248
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To obtain a more global view of the possible ability of
Pim1 to enhance c-MYC transcriptional activity, we first
u s e d  a n  i n d u c i b l e  M y c  s y s t e m  ( M Y C - E R ,  i n  w h i c h  c -
MYC is fused to a mutant estrogen receptor that
responds to 4-hydroxytamoxifen) to identify Myc respon-
sive target genes in RWPE1 prostate cells. We generated
stable RWPE1-Neo/MYC-ER and RWPE1-Pim1/MYC-
ER cells (Figure 7A). Affymetrix genechip profiling after
24-hr 4-hydroxytamoxifen (4OHT) induction identified
129 c-Myc target genes that were up-regulated or down-
regulated in RWPE1-Neo/MYC-ER cells. We then com-
pared these with the genes whose expression is altered by
Pim1 expression in the RWPE1-Pim1/MYC-ER (with
vehicle treatment) cells. A considerable portion (53
genes, 41%) of the 129 Myc target genes was also altered
by Pim1 expression (Table 1). In addition, mRNA expres-
sion of some Pim1/MYC target genes in Table 1 was also
confirmed in LNCaP and DU145 cells by RT-PCR (Figure
7B) although as expected, there was some variability
probably due to the different genetic contexts of these
malignant cell lines. LAMC2, MT1F and UPP1, for exam-
ple, were up-regulated in Pim1-expressing LNCaP cells
Figure 7 Examination of gene expression profile using MYC-ER inducible system in RWPE1 cells and its validation of selected genes in LN-
CaP and DU145 cells. (A) A MYC-ER inducible system was established in RWPE1 prostate cells and shown is western blot analysis of stable protein 
expression of MYC-ER, Pim1 and Actin (arrows) in RWPE1 cell lines. * marks a non-specific band. (B) RT-PCR confirmed mRNA expression of several 
MYC/Pim1 target genes selected from Table 1 in LNCaP-Pim1 and DU145-Pim1 cells. Arrows indicate selected genes that are consistently regulated 
by Pim1 in DU145 and LNCaP cells.Table 1: List of common genes altered by Myc induction and by Pim1 expression in RWPE1-MYC-ER cells
Probe Set ID Gene Symbol Gene Title Regulation
209101_at CTGF connective tissue growth factor Up
222247_at DXS542 X-linked retinopathy protein-like Up
201631_s_at IER3 immediate early response 3 Up
202267_at LAMC2 laminin, gamma 2 Up
217165_x_at MT1F metallothionein 1F Up
212185_x_at MT2A metallothionein 2A Up
213421_x_at PRSS3 protease, serine, 3 Up
209277_at TFPI2 tissue factor pathway inhibitor 2 Up
203234_at UPP1 uridine phosphorylase 1 Up
207275_s_at ACSL1 acyl-CoA synthetase long-chain family member 1 Down
204151_x_at AKR1C1 aldo-keto reductase family 1, member C1 Down
211653_x_at AKR1C2 aldo-keto reductase family 1, member C2 Down
205623_at ALDH3A1 aldehyde dehydrogenase 3 family, memberA1 Down
204942_s_at ALDH3B2 aldehyde dehydrogenase 3 family, member B2 Down
208498_s_at AMY1A/-2B amylase, alpha 1A/1B/1C/2A/2B Down
209546_s_at APOL1 apolipoprotein L, 1 Down
39248_at AQP3 aquaporin 3 (Gill blood group) Down
204820_s_at BTN3A2/3 butyrophilin, subfamily 3, member A2/A3 Down
212067_s_at C1R complement component 1, r subcomponent Down
218983_at C1RL complement component 1, r subcomponent-like Down
202357_s_at C2, CFB complement component 2/complement factor B Down
214164_x_at CA12 carbonic anhydrase XII Down
209301_at CA2 carbonic anhydrase II Down
209771_x_at CD24 CD24 molecule Down
213182_x_at CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) Down
201428_at CLDN4 claudin 4 Down
219529_at CLIC3 chloride intracellular channel 3 Down
204085_s_at CLN5 ceroid-lipofuscinosis, neuronal 5 Down
201117_s_at CPE carboxypeptidase E Down
201372_s_at CUL3 cullin 3 Down
218986_s_at DDX60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 Down
204646_at DPYD dihydropyrimidine dehydrogenase Down
207793_s_at EPB41 erythrocyte membrane protein band 4.1 Down
204569_at ICK intestinal cell (MAK-like) kinase Down
206785_s_at KLRC1/2 killer cell lectin-like receptor subfamily C, member1/2 Down
207723_s_at KLRC3 killer cell lectin-like receptor subfamily C, member 3 Down
207761_s_at METTL7A methyltransferase like 7A Down
209596_at MXRA5 matrix-remodelling associated 5 Down
205220_at NIACR2 niacin receptor 2 Down
213075_at OLFML2A olfactomedin-like 2A Down
203895_at PLCB4 phospholipase C, beta 4 Down
202917_s_at S100A8 S100 calcium binding protein A8 DownKim et al. BMC Cancer 2010, 10:248
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and genes like CDKN1C, CUL3, SOD2 and VAV3 were
repressed in Pim1-expressing DU145 and/or LNCaP
cells. These results strongly support the notion that Pim1
cooperates with c-Myc in prostate cancer at least in part
by modulating c-Myc-transcriptional activity.
c-MYC inhibition by 10058-F4 treatment or RNA 
interference abrogates in vitro cellular growth and alters 
target gene expression of Pim1-expressing prostate cancer 
cells
To examine if increased c-MYC activity truly contributes
to promote tumorigenicity in Pim1-expressing cells, we
inhibited c-MYC activity with 10058-F4, a small molecule
c-Myc inhibitor. 10058-F4 is known to inhibit hetero-
dimerization between c-Myc and Max, so c-Myc is no
longer able to trans-activate its transcriptional target
genes [39-41]. In soft agar assays, 10058-F4 dramatically
suppressed colony formation of LNCaP-Pim1 and
DU145-Pim1 cells (Figure 8A). Next, we treated cells with
different doses of the inhibitor (0, 50, 100 and 200 uM).
Interestingly, 10058-F4 inhibited c-MYC expression itself
in LNCaP cells as shown previously but not in DU145
cells (Figure 8B). This phenomenon, where 10058-F4
treatment reduces MYC protein levels in some cell types
but not others, even though it inhibits MYC activity in
both types of cells, has been noted previously [40,41].
Remarkably, 10058-F4 also repressed both the endoge-
nous human and transgenic murine Pim1 protein expres-
sion in both cell lines (Figure 8B). This effect is not due to
a global, non-specific effect on protein expression since
neither beta-Actin expression used as a loading control in
both cells nor MYC in DU145 cells were changed by
inhibitor treatment (Figure 8B). To determine if 10058-F4
treatment affects Pim1 expression at the protein or
mRNA levels, we performed RT-PCR to detect the trans-
fected murine Pim1 [24] in LNCaP and DU145 cells.
Pim1 mRNA levels were not dramatically changed after
inhibitor treatment (Figure 8B), suggesting that 10058-F4
may inhibit Pim1 protein levels via post-translational reg-
ulation in addition to c-MYC transcriptional activity.
This novel function of c-MYC inhibitor controlling
Pim1 protein expression can not let us examine if
decreased tumorigenicity by c-MYC inhibitor is due to
inhibited c-MYC activity, repressed Pim1 expression or
both. Therefore, to prove that Pim1-induced tumorige-
nicity is through c-MYC activity, it is necessary to selec-
tively inhibit c-MYC using small hairpin RNA (shRNA).
As shown in Figure 8, depending on the levels of c-MYC
repression, cells with ~50% c-MYC knock-down (sh1)
displayed significant reversal in target gene expression
such as LAMC2 and VAV3, but cells with ~25% c-MYC
knock-down (sh2) only showed relatively minor change
(Figure 8C and 8D). Overall, these results support the
notion that MYC is an important mediator for some of
the Pim1 effects observed in this model.
Discussion
Recent studies have increasingly implicated overexpres-
sion of the PIM1 kinase in several human tumors, includ-
ing lymphomas, leukemia's, gastrointestinal, pancreatic
and prostate cancers [9]. In human prostate cancer,
whether PIM1 plays a role in tumor initiation and/or
tumor progression has not been clearly defined. Some
studies have found absent or weak expression of PIM1 in
most high-grade prostatic intraepithelial neoplasia
(HGPIN) lesions, the putative precursor lesion for pros-
tate cancer [19], consistent with a role for PIM1 in tumor
progression, rather than tumor initiation. By contrast,
others have noted PIM1 overexpression in a significant
fraction of HGPIN lesions [42,43]. There has been limited
in vivo experimental investigation of Pim1 oncogenic
activity in the prostate. One study used, PC3, an aggres-
sive androgen-independent human prostate cancer cell
line, to examine in vivo tumorigenicity of Pim1. The
results demonstrated that tumor growth in Pim1-
expressing PC3 cells was accelerated compared to control
208607_s_at SAA1/2 serum amyloid A1/A2 Down
213988_s_at SAT1 spermidine/spermine N1-acetyltransferase 1 Down
211361_s_at SERPINB13 serpin peptidase inhibitor, clade B, member 13 Down
215223_s_at SOD2 superoxide dismutase 2, mitochondrial Down
203787_at SSBP2 single-stranded DNA binding protein 2 Down
214970_s_at ST6GAL1 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 Down
202644_s_at TNFAIP3 tumor necrosis factor, alpha-induced protein 3 Down
202687_s_at TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 Down
213293_s_at TRIM22 tripartite motif-containing 22 Down
208596_s_at UGT1A1-10 UDP glucuronosyltransferase 1 family, A1/A3-A10 Down
218806_s_at VAV3 vav 3 guanine nucleotide exchange factor Down
Table 1: List of common genes altered by Myc induction and by Pim1 expression in RWPE1-MYC-ER cells (Continued)Kim et al. BMC Cancer 2010, 10:248
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cells, and this could be partly due to c-MYC protein
induction [21]. Our previous study examining tumori-
genic potential of Pim1 in the benign human prostate epi-
thelial cell line RWPE1 indicates that Pim1
overexpression alone is not sufficient for the malignant
conversion of these cells [25], a finding that was con-
firmed in the current study. Rather, time-dependent addi-
tional genetic events, propelled by chromosomal
instability appeared to be required for Pim1-expressing
RWPE1 cells to form tumors in vivo [25]. These conclu-
sions are supported by our recent observations that Pim1
expression resulted in mild pathological alterations in
normal adult mouse prostate epithelial cells using a tissue
recombination system, but it greatly accelerated the pro-
gression of c-MYC-initiated tumors [44].
Our findings that Pim1 expression could significantly
promote tumorigenicity in established human prostate
cancer cell lines (LNCaP and DU145) indicate a clear role
for Pim1 in tumor progression. The data also showed
effects of Pim1 in promoting tumor proliferation and
inhibiting apoptosis in vivo. Interestingly, these effects of
Pim1 are not always obvious in cells grown on plastic tis-
sue culture plates in vitro. Notably, both LNCaP and
DU145 cells express appreciable levels of Pim1, and it is
likely that at least part of the mechanism by which Pim1
expression promotes tumorigenicity in these cells is via
enhancing c-MYC transcriptional activity. This hypothe-
sis is supported by the results of the luciferase assays
showing that the transcriptional activity of c-MYC was
significantly enhanced by Pim1 in a kinase-dependent
manner, by gene expression profiling using a MYC-ER
inducible system, and by the finding that changes in tar-
get gene expression were reversed by c-MYC inhibition
when small hairpin RNA (shRNA) against c-MYC was
introduced.
Our finding that 10058-F4, a small molecule c-Myc
inhibitor could target both Pim1 protein expression and
c-Myc transcriptional activity in both androgen-depen-
Figure 8 c-MYC inhibition either by a small molecule inhibitor (10058-F4) or by RNA interference (RNAi) causes in vitro growth arrest and 
alters target gene expression. (A) c-Myc inhibitor (10058-F4) abrogated colony formation of LNCaP and DU145 cells in soft agar assay. # indicates 
no colonies. *P < 0.0001, **P < 0.002. (B) Control and Pim1-expressing LNCaP and DU145 cells were treated with different doses (0, 50, 100 and 200 
uM) of 10058-F4. Note that 10058-F4 inhibits protein expression of Pim1, but not Pim1 mRNA. (C) Control and two small hairpin RNA constructs (sh1 
and sh2) against c-MYC were transfected in LNCaP-Pim1 cells to knock down c-MYC expression. Relative c-MYC expression is shown. (D) Expression 
of some target genes (LAMC2 and VAV3) in LNCaP cells was reversed by repression of c-MYC levels in a dose-dependent manner. * indicates altered 
target gene expression by c-MYC knock-down.Kim et al. BMC Cancer 2010, 10:248
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dent and -independent prostate cancer cells is intriguing
and of potential clinical significance. Since Pim1 and c-
Myc cooperate to promote the development of lym-
phoma [16-18] and prostate cancer [19-21,44], targeting
both molecules with one drug could dramatically
enhance the efficacy of the treatment in cancer patients.
However, a limitation of using this particular inhibitor as
a drug relates to short half-life because it is rapidly
metabolized in vivo [45]. Efforts to improve the efficacy
of this compound [46] could lead to a potentially impor-
tant way to target MYC/Pim1-expressing cancers.
Conclusion
It is important to determine the roles that specifically rel-
evant oncogenes play in the course of tumorigenesis in
vivo in order to aid appropriate therapeutic targeting. We
have shown that Pim1 promotes the tumorigenicity of
human prostate cells (LNCaP and DU145) partially by
enhancing activities of the MYC and AR signaling path-
ways. Our findings support the targeting of Pim1 in
human cancer and suggest a potential for using the same
inhibitor (such as 10058-F4) to target both MYC and
PIM1 in human tumors.
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